Press Releases
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75% enrollment. TORONTO, ON, May 7, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that the results from its Phase II study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the Journal of the American Heart Association ("JAHA")...
PAN GLOBAL REPORTS SURFACE HIGH-GRADE GOLD WITH 20.2 g/t OVER 5.0 METERS AT CÁRMENES PROJECT, SPAIN
TSXV: PGZ | OTCQB: PGZFF | FRA: 2EU Saw-cut sampling returned 20.2 g/t gold over 5.0 meters at surface confirming higher grades well beyond the historical Providencia mine workings Discovery of extensive sulphide and hematite breccia exposed at the newly accessed 1,438m Level of mine workings indicates the system is widening and open at depth Further underground and surface sampling in progress Drill program expanded to eight drillholes Ongoing district-scale exploration at more than 25 high-priority targets across the Cármenes Project area VANCOUVER, BC, May 7, 2026 /PRNewswire/ - Pan Global Resources Inc. ("Pan Global" or the "Company") (TSXV: PGZ) (OTCQB: PGZFF) (FRA: 2EU) is pleased to announce new twin saw-cut channel sampling at surface has verified high-grade gold mineralization, returning 20.2 g/t gold over 5.0 meters. Underground mapping of historical mine workings has confirmed a substantial widening of the mineralized system at depth at the Providencia target ("Providencia"), within the Cármenes Project ("Cármenes") on the southeastern extension of the Rio Narcea Gold Belt in northern Spain...
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company's development program in Multiple System Atrophy (MSA) will be delivered at multiple medical conferences in May 2026...
Kane Biotech Announces New Private Placement Offering
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 07, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 20,000,000 units of the Company (“Units”) at a price of $0.05 per Unit for gross proceeds of up to $1,000,000. Each Unit shall be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a “Warrant”)...
MarketWise Reports Net Revenue of $77.0 Million and Net Loss of $0.6 Million for First Quarter 2026; Q1 Billings Increase 15% YoY; Announced Quarterly Regular and Special Dividends totaling $0.45 per Class A share; Affirms FY 2026 Guidance of Billings of $300 Million and CFFO of $50 Million; Board Authorizes New $50M Share Buyback Program
BALTIMORE, May 07, 2026 (GLOBE NEWSWIRE) -- MarketWise, Inc. (NASDAQ: MKTW) (“MarketWise” or the “Company”), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today reported financial results for first quarter 2026.(1)
USANA's People-First Culture Earns Spot on USA TODAY Top Workplaces List
SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- USANA Health Sciences (NYSE: USNA), a global leader in cellular nutrition, is proud to announce it has earned a spot on the prestigious 2026 USA TODAY Top Workplaces award list. The award honors organizations with 150 or more employees that have created exceptional, people-first cultures...
Natural Grocers® Celebrates Washington Day with a Special Gift and Savings May 10-12, 2026
LAKEWOOD, Colo., May 7, 2026 /PRNewswire/ -- Natural Grocers, the leading family-operated organic and natural grocery retailer in the U.S., invites customers to its annual Washington Day event, May 10–12 at its five Washington stores.
DLP Resources Announces Brokered LIFE Offering for Gross Proceeds of up to C$5 Million
Cranbrook, British Columbia--(Newsfile Corp. - May 7, 2026) - DLP Resources Inc. (TSXV: DLP) (OTCQB: DLPRF) (FSE: J8C) ("DLP" or the "Company") is pleased to announce that it has entered into an agreement with Red Cloud Securities Inc. ("Red Cloud") to act as sole agent and bookrunner in connection with a "best efforts" private placement (the "Marketed Offering") for gross proceeds of up to C$5,000,000 from the sale of up to 20,000,000 units of the Company (the "Units") at a price of C$0.25 per Unit (the "Offering Price"). Each Unit will consist of one common share of the Company (each, a "Common Share") and one common share purchase warrant (each, a "Warrant")...
Aurora Spine Announces Issuance of Fourth U.S. Patent Covering DEXA Technology® Bone Density-Matched Implants
CARLSBAD, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices for spinal surgery, today announced the issuance of its fourth U.S. patent related to Aurora's proprietary DEXA Technology platform...
Stack Capital Group Inc. Reports Q1-2026 Financial Results
TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX:STCK) today announced its financial results for the period ended March 31, 2026. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated.
Nuveen Churchill Direct Lending Corp. Announces First Quarter 2026 Results
NEW YORK--(BUSINESS WIRE)--Nuveen Churchill Direct Lending Corp. (NYSE: NCDL) (“NCDL” or the “Company”), a business development company externally managed by its investment adviser, Churchill DLC Advisor LLC (the “Adviser”), and by its sub-adviser, Churchill Asset Management LLC (“Churchill”), today reported financial results for the first quarter ended March 31, 2026. Financial Highlights for the Quarter Ended March 31, 2026 Net investment income of $0.41 per share Net realized and unrealized...
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market conditions and other factors, $350.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act...
Entrada Therapeutics Reports First Quarter 2026 Financial Results
500 - Internal server error. Server Error 500 - Internal server error.
GreenLight Metals Signs Binding Term Sheet with Barrick for Staged Earn-In Joint Venture at Kalium Canyon Project in Nevada's Walker Lane
Medford, Wisconsin--(Newsfile Corp. - May 7, 2026) - GreenLight Metals Inc. (TSXV: GRL) (OTCQB: GRLMF) ("GreenLight" or the "Company") is pleased to announce that, through its wholly owned subsidiary Green Light Wisconsin LLC, it has signed a binding term sheet (the "Term Sheet") with a wholly owned subsidiary of Barrick Mining Corporation ("Barrick"), for a proposed staged earn-in and joint venture at GreenLight's Kalium Canyon gold project in Esmeralda County, Nevada (the "Property" or "Kalium Canyon"). Pursuant to the Term Sheet, Barrick may earn an initial 60% project-level equity interest by completing US$7.5 million in Qualifying Exploration Expenditures ("QEE"), limited to direct project costs, and making aggregate cash payments of US$1.0 million to GreenLight over a six-year Stage 1 earn-in period...
TerrAscend Reports First Quarter 2026 Financial Results
Net Revenue of $65.5 million and Gross Profit Margin of 52.8% for Q1 2026 Q1 2026 Net Cash Provided from Continuing Operations of $8.7 million, representing 13.3% Operating Cash Flow Yield 1 Q1 2026 Free Cash Flow1 of $7.8 million, representing 10.3% Free Cash Flow Yield 1 15th Consecutive Quarter of Positive Cash Flow from Continuing Operations and 11th Consecutive Quarter of Positive Free Cash Flow1 TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today reported its financial results for the first quarter ended March 31, 2026. All amounts are expressed in U.S. dollars and are prepared under U.S. Generally Accepted Accounting Principles (GAAP), unless indicated otherwise...
Persistent Achieves Databricks Brickbuilder Specialization for Healthcare & Life Sciences, Expanding Production-Ready Data and AI Solutions For Regulated Environments
Enables HLS organizations to unify multimodal data, accelerate clinical and real-world evidence workflows, and operationalize governed AI at scale SANTA CLARA, Calif. and PUNE, India, May 7, 2026 /PRNewswire/ -- Persistent Systems (BSE: 533179) (NSE: PERSISTENT), a global Digital Engineering and Enterprise Modernization leader, today announced that it has achieved the Databricks Brickbuilder Specialization for Healthcare and Life Sciences (HLS)...
Gilat to Present at Upcoming Investor Conferences
PETAH TIKVA, Israel, May 07, 2026 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that Mr. Gil Benyamini, Chief Financial Officer, will present at and attend the following upcoming conferences:
Resolute Holdings Reports First Quarter 2026 Results
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Resolute Holdings Management, Inc. (“Resolute Holdings”) (NYSE: RHLD), an operating management company responsible for providing management services to the operating businesses of GPGI, Inc. (“GPGI”) (NYSE: GPGI), today reported financial results for its fiscal first quarter ended March 31, 2026. Resolute Holdings reported first quarter earnings per share attributable to common stockholders of $7.19 compared to ($0.39) in the prior year and Non-GAAP Fee-Related Earnings per share of $0.69 compared to ($0.07) in the prior year...
Appian Announces First Quarter 2026 Financial Results
Cloud subscriptions revenue increased 25% year-over-year to $124.5 million, while cash flow provided by operations totaled $48.8 million Cloud subscriptions revenue increased 25% year-over-year to $124.5 million, while cash flow provided by operations totaled $48.8 million
Xometry Reports Record First Quarter 2026 Results
NORTH BETHESDA, Md., May 07, 2026 (GLOBE NEWSWIRE) -- Xometry, Inc. (NASDAQ: XMTR), the global AI-native marketplace connecting buyers and suppliers of custom manufacturing, today announced its financial results for the first quarter ended March 31, 2026.
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
1Q26 Total Revenue of ~$71M Delivers ~ 45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial Cancer SAN CARLOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2026 financial results, business achievements, and corporate updates...
GPGI Reports First Quarter 2026 Results
CompoSecure delivers record ROS-driven results Husky impacted by unexpected market headwinds due to oil and resin price shock and continued tariff uncertainty ROS deployment accelerating across the enterprise First Quarter Highlights Results compared to prior year period unless otherwise noted; pro forma metrics inclusive of Husky Technologies for full quarter. Pro Forma Adjusted Net Sales of $421.2 million, up 3% GAAP Net Loss of $235.0 million Pro Forma Adj...
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
ROCKVILLE, Md., May 7, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking place May 11-15, 2026, in Boston, Massachusetts.
Tripadvisor, Inc. Earnings Press Release Available on Company's Investor Relations Site
NEEDHAM, Mass., May 7, 2026 /PRNewswire/ -- Tripadvisor, Inc. (NASDAQ: TRIP) issued its first quarter 2026 earnings press release which is available now at ir.tripadvisor.com.
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2026 results and recent business performance. “Our first quarter of 2026 delivered strong financial performance, driven by significantly improved net price and mid-single digit prescription growth for LINZESS, positioning us well to achieve our full-y...
Amazon Pharmacy Expands Access to New Ozempic® Pill via Same-Day Delivery, Kiosks
SEATTLE--(BUSINESS WIRE)--Amazon Pharmacy (NASDAQ: AMZN), a full-service digital pharmacy that delivers medications directly to customers' homes, is expanding access to Novo Nordisk's Ozempic pill, the only FDA-approved oral GLP-1 medication to treat type 2 diabetes. Amazon Pharmacy will offer Same-Day prescription delivery and pickup within minutes through in-office kiosk locations soon, addressing a critical access gap for the more than 36 million Americans living with type 2 diabetes. Custo...
Pagaya Appoints Chief Strategy Officer Jonathan Dobres as CFO, Succeeding Evangelos Perros
NEW YORK--(BUSINESS WIRE)--Pagaya Technologies LTD. (NASDAQ: PGY) ("Pagaya" or the “Company”), a global technology company delivering AI-driven product solutions for the financial ecosystem, announced today the appointment of Chief Strategy Officer Jonathan Dobres, as Chief Financial Officer, effective June 15, 2026. Dobres will be succeeding Evangelos Perros, who will remain in his current role until June 15, 2026. Perros will remain with the Company through December 31st, 2026 serving as a St...
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
NEW HAVEN, Conn., May 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 14, 2026 at 8:30 a.m. ET to discuss its first quarter 2026 financial results and provide a corporate update...
Shake Shack Appoints Michelle Hook as Chief Financial Officer
NEW YORK--(BUSINESS WIRE)--Shake Shack Inc. ("Shake Shack" or the "Company") (NYSE:SHAK) today announced the appointment of Michelle Hook as the Company's Chief Financial Officer, effective May 11, 2026. Ms. Hook joins Shake Shack's executive leadership team and will be responsible for leading financial operations across the Company, including accounting and treasury, financial planning and analysis, tax, investor relations and external reporting. Ms. Hook brings more than two decades of financ...
Grounded Lithium Provides Oil & Gas Operations Update, Announces Annual General and Special Meeting and Option Grant
CALGARY, AB, May 7, 2026 /PRNewswire/ - (TSXV: GRD) ( OTC: GRDAF) - Grounded Lithium Corp. ("GLC" or the "Company") announces continued success with our resource diversification strategy into oil and gas operations. Further to our press release on April 15, 2026, we are now pleased to report that production for the two wells drilled off a single pad averaged over 120 barrels per day for the month of April...
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events -- -- Markers of kidney function via eGFR, Cystatin C and magnesium were all within normal ranges and comparable to placebo -- -- Observed lower plasma exposure in Cohort 1 participants who are all between six and 17 years of age when compared with healthy adult volunteers; A similar trend was seen between recently received juvenile and adult NHP PK data -- -- Consequently, Cohort 1 demonstrated an increase of 2.36% in dystrophin over a baseline of 4.00% and an increase of 2.31% in exon skipping over a baseline of 2.66% in treated participants -- -- Statistically significant and potentially differentiated improvement in treated participants versus placebo in Time to Rise velocity, a clinically validated functional measurement -- -- Company's updated PK modeling predicts Cohort 2, building upon Cohort 1 data and combined with the recently received juvenile NHP data, will result in a significant increase of plasma AUC and substantially higher dystrophin levels with continued benefit in muscle function -- -- Company has initiated dosing of ELEVATE-44-201 Cohort 2 at the increased dose of 12 mg/kg and is on track to report data by year-end 2026 -- -- Entrada to host investor webcast and conference call today, Thursday, May 7, at 8:30 a.m. ET -- BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-44-201 clinical study...
AAON Reports First Quarter 2026 Results with Record Sales and Backlog, Robust Earnings Growth, and Raises Full-Year Guidance
First Quarter 2026 Results (All comparisons are year-over-year, unless otherwise noted) Delivered record sales and accelerated earnings growth on strong demand and expanding production throughput Net sales grew 54.3% to a record $496.9 million Operating margins reflected early benefits from improving utilization, with margin improvement expected to build as capacity absorption improves GAAP diluted EPS increased 37.1% to $0.48 reflecting strong earnings growth on higher volume Total backlog increased 107.4% to a record $2.1 billion, driven by continued strength from the data center market Raises 2026 Outlook 2026 outlook now reflects revenue growth of 40%-45%% and gross margins of approximately 27-28%, supported by record backlog, expanded capacity, and improving operational execution TULSA, Okla., May 7, 2026 /PRNewswire/ -- AAON, INC...
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer's disease agitation and NMRA-898 in schizophrenia with clinical data expected for each program in the second half of 2026 Strong financial position with $147.1 million in cash and cash equivalents expected to support operations into the third quarter of 2027 WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update...
OppFi Reports First Quarter 2026 Results, Record Quarterly Revenue
Total revenue increased 8.3% year over year to $151.9 million, a Company record for the first quarter Net income increased 165.0% year over year to $54.0 million Adjusted net income1 decreased 11.2% year over year to $30.0 million Board approves new $40 million Share Repurchase Program CHICAGO, May 7, 2026 /PRNewswire/ -- OppFi Inc. (NYSE: OPFI) ("OppFi" or the "Company"), a tech-enabled digital finance platform that partners with banks to offer financial products and services to everyday Americans, today reported financial results for the first quarter ended March 31, 2026. "Operationally, OppFi had a healthy start to 2026, generating record first-quarter revenue, which reflects the strength of our core operations...
Chicago Atlantic Real Estate Finance Announces First Quarter 2026 Financial Results
CHICAGO, May 07, 2026 (GLOBE NEWSWIRE) -- Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, today announced its financial results for the first quarter ended March 31, 2026. Peter Sack, Co-Chief Executive Officer, noted, “Chicago Atlantic delivered stable results for the first quarter of 2026 in an unstable macro environment by continuing to differentiate ourselves from other capital providers...
Gogo Announces First Quarter Results
Total Revenue of $226.3 million; Equipment Revenue up 22% Year-Over-Year to $38.6 million on Record ATG Unit Sales Net Income of $13.1 million, Adjusted EBITDA 1 of $53.3 million, up 41% Sequentially Gogo Galileo and 5G Expected to Ramp in 2026 BROOMFIELD, Colo., May 07, 2026 (GLOBE NEWSWIRE) -- Gogo Inc. (NASDAQ: GOGO) (“Gogo” or the “Company”), a leading global provider of broadband connectivity services for the business and military/government aviation markets, today announced its financial results for the quarter ended March 31, 2026...
Codere Online Reports Financial Results for the First Quarter 2026
The Company delivered record quarterly net gaming revenue of €64.4 million and Adj. EBITDA of €6.0 million Total revenue was €60.3 mm in Q1 2026, while net gaming revenue1 was €64.4 mm, 13% above Q1 2025.
USA Rare Earth Announces Date for Release of First Quarter 2026 Results and Conference Call
STILLWATER, Okla., May 07, 2026 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (the Company), today announced that it will release financial results for the quarterly period ended March 31, 2026, after U.S. markets close on Wednesday, May 13, 2026.
Westhaven Returns 54m Grading 8.99 g/t Au & 55 g/t Ag from Resource In-Fill Drilling and Initiates South Zone Pre-Feasibility Study, Shovelnose Gold and Silver Project, Southern British Columbia
VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- Westhaven Gold Corp. (TSX-V: WHN) (OTCQB: WTHVF) (“Westhaven” or the “Company”) is pleased to provide an update on its 2026 field activities at the Shovelnose gold and silver project ("Shovelnose"), in southern British Columbia, including initial mineral resource in-fill drilling results and the commencement of a Prefeasibility Study ("PFS") evaluating potential mine development at the South Zone deposit. This work is being funded under a strategic earn-in agreement with Dundee Corporation (“Dundee”), whereby Dundee may earn up to a 60% interest in Westhaven's four Spences Bridge Gold Belt properties through up to CDN$85,000,000 in staged project expenditures...
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory - Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027 -Selective EP300 degraders with potential in multiple myeloma and other hematological malignancies with IND anticipated in 2027 - Strong balance sheet with cash, cash equivalents, and marketable securities of approximately $184 million ; cash runway into the first half of 2028 WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the quarter ended March 31, 2026...
AI Financial Corporation Announces Commercial Agreement with SuperQ Quantum to Support Post-Quantum Security Initiatives
LAS VEGAS, May 07, 2026 (GLOBE NEWSWIRE) -- AI Financial Corporation (NASDAQ:AIFC)(FRA:5AR1) ("AiFi" or the "Company"), a fintech company providing blockchain-powered payment, trading, and settlement infrastructure for digital assets, today announced a strategic commercial agreement with SuperQ Quantum Computing Inc. ("SuperQ Quantum" or "SuperQ") (CSE: QBTQ; OTCQB: QBTQF; Frankfurt: 25X), a company specializing in hybrid quantum computing and post-quantum cybersecurity. The partnership is focused on supporting infrastructure security initiatives across portions of AiFi's digital asset platform as digital finance systems continue to evolve...
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance RAP-219 Phase 3 program in FOS remains on track for initiation in the second quarter of 2026 Pipeline programs, including RAP-219 long-acting injectable formulation, RAP-219 in primary generalized tonic-clonic seizures, and α6β4 nAChR in chronic pain and migraine, continue to advance Strategic collaboration and license agreement entered into with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China across indications Ended the first quarter of 2026 with $476.8 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter ending March 31, 2026, and provided a business update. “We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling new follow-up Phase 2a data recently presented at AAN that further reinforces RAP-219's treatment effect in focal onset seizures and builds confidence as we enter our Phase 3 trials,” said Abraham N...
Datadog Announces First Quarter 2026 Financial Results
First quarter revenue grew 32% year-over-year to $1,006 million Robust growth of larger customers, with about 4,550 $100k+ ARR customers, up from about 3,770 a year ago Launched MCP Server, Bits AI Security Agent, GPU Monitoring, and Experiments for general availability NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Datadog, Inc. (NASDAQ:DDOG), the leading AI-powered observability and security platform, today announced financial results for its first quarter ended March 31, 2026. "Datadog executed to a strong quarter, with 32% year-over-year revenue growth, $335 million in operating cash flow, and $289 million in free cash flow," said Olivier Pomel, co-founder and CEO of Datadog...
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 Presented positive interim Phase 1/2 clinical data of GSPT1-directed MGD MRT-2359 in combination with an AR inhibitor in mCRPC patients with AR mutations; initiation of Phase 2 study evaluating MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations planned for Q3 2026 VAV1-directed MGD MRT-6160 advancing toward anticipated initiation by Novartis of multiple Phase 2 studies in immune-mediated diseases Preclinical data presented at AACR highlight a novel cyclin E1-directed MGD with superior selectivity and reduced off-target activity compared to CDK2 inhibitors; IND submission anticipated in H2 2026 Strong balance sheet with cash, cash equivalents, restricted cash, and marketable securities of $671 million, expected to support operations into 2029 BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the first quarter ended March 31, 2026. “We continue to make excellent progress advancing multiple programs through the clinic, with all three of our clinical-stage programs approaching Phase 2 trial initiations,” said Markus Warmuth, M.D...
U.S. Energy Corp. Reports First Quarter 2026 Results and Highlights Transformative Operational and Commercial Progress at Big Sky Carbon Hub
Achieves Final Investment Decision and Executes Fixed-Scope EPC Contract on Phase 1 Processing Facility Signs Five-Year, 100% Take-or-Pay Helium Offtake Agreement with Investment-Grade Industrial Gas Counterparty Completes Phase 1 Capital Stack and Suspends Equity Line of Credit HOUSTON, May 07, 2026 (GLOBE NEWSWIRE) -- U.S. Energy Corporation (NASDAQ: USEG) (“U.S. Energy” or the “Company”), an integrated industrial gas, energy, and carbon management company, today reported financial and operating results for the three months ended March 31, 2026, while highlighting significant operational, commercial, and financial milestones achieved during the quarter that materially advance the development of the Company's Big Sky Carbon Hub, its flagship project in Montana. MANAGEMENT COMMENTS “The first quarter of 2026 marked the inflection point in U.S. Energy's transformation,” said Ryan Smith, President and Chief Executive Officer of U.S. Energy Corp. “In the past 90 days, we reached Final Investment Decision on our Phase 1 processing facility at the Big Sky Carbon Hub, executed a fixed-scope EPC contract with CANUSA -- an experienced engineering firm with a track record in gas processing and energy infrastructure, -- completed our Phase 1 capital stack, formally suspended our equity line of credit, and signed a five-year, 100% take-or-pay helium offtake agreement with an investment-grade global industrial gas counterparty...
Dundee Corporation Announces Results of In-Fill Drilling at Westhaven's Shovelnose Gold and Silver Project, Southern British Columbia
TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Dundee Corporation (TSX: DC.A) (“Dundee” or the “Corporation”) is pleased to provide an update on Westhaven Gold Corp's (“Westhaven”) 2026 field activities at the Shovelnose gold and silver project ("Shovelnose"), in southern British Columbia, including initial mineral resource in-fill drilling results and the commencement of a Prefeasibility Study ("PFS") evaluating potential mine development at the South Zone deposit. On February 23, 2026, the Corporation completed a strategic earn-in agreement with Westhaven, whereby Dundee may earn up to a 60% interest in Westhaven's four Spences Bridge Gold Belt properties through up to CDN$85,000,000 in staged project expenditures...
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
Q1 2026 Vafseo (vadadustat) net product revenues grew to $15.8 million ; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025 Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST CAMBRIDGE, Mass...
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ERA 2026 with initial Phase 1 PK/PD data expected mid-2026 Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; anticipate data from all ongoing trials in 2026 Secured $110 million private placement led by top-tier healthcare investors WELLESLEY HILLS, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2026, and provided business updates...
Widmer Brothers Launches “Stay Sunny” Campaign, a Full Brand Refresh Across Its Portfolio
PORTLAND, Ore., May 07, 2026 (GLOBE NEWSWIRE) -- Widmer Brothers Brewing , the creator of the Original American Hefeweizen and a craft brand by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), today announced the launch of ‘Stay Sunny', a full brand refresh across its entire Hefe portfolio, marking a new chapter for one of Oregon's most iconic breweries and the originators of the American Hefeweizen...
Weight Watchers Announces First Quarter 2026 Results
Total End of Period Subscribers of 2.7 million; End of Period Clinical Subscribers of 197 thousand, up 46% year-over-year Revenue of $168 million; Clinical Subscription Revenue of $39 million, up 32% year-over-year Reaffirms Full Year 2026 Financial Guidance Announces Fully Subscribed Debt Prepayment Solicitation as Part of Actions Expected to Reduce Debt by $42 Million NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the first quarter of fiscal 2026 ended March 31, 20261 in this Earnings Press Release and a Shareholder Letter issued today and posted on the Company's Corporate Website . “We remain confident in our strategy to build the industry-leading weight health platform...
NexMetals Expands the Selebi System Intersecting 10.40 Metres of 6.82% CuEq (3.09% Cu, 1.83% Ni) at Selebi Main, 320 Metres Beyond the 2024 MRE
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - NexMetals Mining Corp. (TSXV: NEXM) (NASDAQ: NEXM) ("NEXM" or the "Company") is pleased to report assay results from its surface drilling program at the Selebi Mines Project in Botswana, targeting the gap between the Selebi Main and North deposits and advancing resource expansion. The Selebi Mines Project comprises two deposits, Selebi Main and Selebi North, which host a combined Mineral Resource of 3.0 Mt at 2.92% CuEq (0.90% Cu and 0.98% Ni) Indicated and 24.7 Mt at 3.40% CuEq (1.50% Cu and 0.92% Ni) Inferred...
Eloro Resources Announces the Commencement of Expansion Diamond Drilling Program Based on Positive Updated MRE Results at Its Iska Iska Project, Southern Bolivia
Key Program Objectives: Expansion Drill Program: The 2026 drilling program at Iska Iska, as part of the Preliminary Economic Assessment (PEA) process, follows the successful completion of the Updated Mineral Resource Estimate (MRE) in late April 2026. Its main objectives are to strategically expand and upgrade the 85.17 million tonnes of Indicated Resources grading 78.38 Ag g/t Eq...
Herbal Dispatch Reports Accelerating Veteran Customer Growth and Expansion of Insurance-Focused Service Channel
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), is pleased to provide an update on the continued growth and expansion of its veteran-focused medical cannabis channel. The Company has experienced sustained acceleration in veteran customer acquisition, driven by targeted outreach, streamlined onboarding, and a dedicated service model tailored to the needs of veterans...
Myers Industries Announces 2026 First Quarter Results
AKRON, Ohio--(BUSINESS WIRE)--Myers Industries Announces 2026 First Quarter Results.
Rare Earths Americas Announces Closing of $63.3 Million Upsized Initial Public Offering
MANCHESTER, Ga.--(BUSINESS WIRE)--Rare Earths Americas, Inc. (“REA” or the “Company”), a critical minerals company advancing a portfolio of prospective heavy rare earths focused projects in the United States and in Brazil, announced today the closing of its upsized initial public offering of 3,333,331 shares of its common stock. The gross proceeds from the offering were approximately $63.3 million, before deducting underwriting discounts and commissions and estimated offering expenses. The shar...
Vistra Reports First Quarter 2026 Results
Earnings Release Highlights GAAP first quarter 2026 Net Income of $1,029 million, including an unrealized gain from hedges expected to settle in future years of $723 million, and Ongoing Operations Adjusted EBITDA1 of $1,494 million. Reaffirmed 2026 Ongoing Operations Adjusted EBITDA1 and Ongoing Operations Adjusted FCFbG1 guidance ranges of $6.8 billion to $7.6 billion and $3.925 billion to $4.725 billion, respectively.3 Vistra's corporate issuer credit rating upgraded to Investment Grade at second major credit rating agency...
Supremex Announces Results for the First Quarter of 2026
Montreal, Quebec--(Newsfile Corp. - May 7, 2026) - Supremex Inc. (TSX: SXP) ("Supremex" or the "Company"), a leading North American manufacturer and marketer of envelopes and a growing provider of paper-based packaging solutions, today announced its results for the first quarter ended March 31, 2026. The Company will hold a conference call to discuss these results today at 9:00 a.m...
Polestar reports Q1 2026 select financial and operational results
GOTHENBURG, Sweden--(BUSINESS WIRE)--Polestar (Nasdaq: PSNY) reports select unaudited financial and operational results for the quarter ended March 31, 2026 (Q1 2026). Michael Lohscheller, Polestar CEO, said: “The first quarter saw us deliver strong volume growth in a very competitive market. With implemented steps to improve our cost base being offset by more challenging market conditions, we are accelerating efforts to adjust our business model, become leaner and improve manufacturing efficie...
Bentley Systems Announces First Quarter 2026 Results
EXTON, Pa.--(BUSINESS WIRE)--Bentley Systems, Incorporated (Nasdaq: BSY) today announced results for its first quarter ended March 31, 2026.
Arrow Electronics Reports First-Quarter 2026 Results
CENTENNIAL, Colo.--(BUSINESS WIRE)--Arrow Electronics, Inc. (NYSE:ARW) today announced financial results for its first quarter of 2026. “The first quarter marked a strong start to 2026 as total revenue, profit margins, and EPS grew significantly year over year, exceeding our guidance ranges,” said Bill Austen, Arrow's interim president and chief executive officer. “We saw continued operational momentum across both Global Components and ECS, supported by an accelerated recovery that spanned geog...
BlackSky Reports First Quarter 2026 Results
HERNDON, Va.--(BUSINESS WIRE)---- $BKSY #earnings--BlackSky Technology Inc. (“BlackSky” or the “Company”) (NYSE: BKSY) announced results for the first quarter ended March 31, 2026. “With up to $160 million in new contract wins, we are rapidly growing revenues driven by the demand for Gen-3 space-based intelligence and AI services,” said Brian E. O'Toole, BlackSky CEO. “We are raising our guidance for the year based on strong year-to-date sales performance, in-year revenue visibility, and accelerated demand for bes...
BETA Technologies to Participate in Upcoming Investor Conferences
SOUTH BURLINGTON, Vt.--(BUSINESS WIRE)--BETA Technologies, Inc. (NYSE: BETA) (“BETA” or “the Company”), an electric aerospace company, today announced its participation at the following upcoming investor conferences: On Wednesday, May 13, 2026, Herman Cueto, Chief Financial Officer and Devon Rothman, Head of Investor Relations and FP&A, will participate in a fireside chat at Bank of America's 33rd Annual Industrials, Transportation & Airlines Key Leaders Conference in New York, NY. On T...
Rockwell Automation to Present at the Wolfe Research 19th Annual Global Transportation and Industrials Conference
MILWAUKEE--(BUSINESS WIRE)--Rockwell Automation, Inc. (NYSE: ROK) SVP and CFO, Christian Rothe; SVP, Lifecycle Services, Matt Fordenwalt; and VP, Investor Relations and Market Strategy, Aijana Zellner, will present at the Wolfe Research 19th Annual Global Transportation and Industrials Conference on Wednesday, May 20, 2026, in New York. The fireside chat will be webcast beginning at approximately 8:40 a.m. EDT and will be available on the Rockwell Automation Investor Relations website at www.ro...
The Middleby Corporation Reports First Quarter Results
ELGIN, Ill.--(BUSINESS WIRE)--The Middleby Corporation (NASDAQ: MIDD), a leading worldwide manufacturer of equipment for the commercial foodservice and food processing industries, today reported net earnings for the first quarter of 2026. Tim FitzGerald, CEO of The Middleby Corporation said, “We delivered an extremely strong first quarter with outperformance at both segments relative to our expectations. Our Commercial Foodservice segment generated 8.1% organic growth, driven by continued doubl...
Stratasys Releases First Quarter 2026 Financial Results
MINNETONKA, Minn. & REHOVOT, Israel--(BUSINESS WIRE)--Stratasys Ltd. (Nasdaq: SSYS), (“Stratasys” or the “Company”), a leader in polymer 3D printing solutions, today announced its financial results for the first quarter ended March 31, 2026. “Our first quarter results reflect the resilience of our operating model in a measured spending environment, demonstrated by positive adjusted EBITDA and operating cash flow," said Dr. Yoav Zeif, CEO of Stratasys. "Recurring revenue from consumables and cus...
Pagaya Reports First Quarter 2026 Results & Raising Full-Year Net Income Guidance
NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--Pagaya Technologies Ltd. (NASDAQ: PGY) (“Pagaya”, the “Company” or “we”), a global technology company delivering artificial intelligence infrastructure for the financial ecosystem, today announced financial results for the first quarter 2026. For additional information, view Pagaya's first quarter 2026 letter to shareholders here. “Our results this quarter demonstrate, once again, that at Pagaya, profitability and disciplined risk management are not...
N-able Announces First Quarter 2026 Results
BURLINGTON, Mass.--(BUSINESS WIRE)--N-able, Inc. (NYSE:NABL), a global cybersecurity company delivering business resilience, today reported results for its first quarter ended March 31, 2026. “We delivered a strong first quarter, driven by improving retention and continued progress across the business,” said N-able president and CEO John Pagliuca. “As AI accelerates both the threat landscape and IT complexity, we believe cybersecurity is reaching an inflection point. Our platform is purpose‑bui...
Genius Sports Reports 31% Revenue Growth and 21% Adjusted EBITDA Growth; Raises 2026 Guidance, Targeting 28% Adjusted EBITDA Margin Following Legend Acquisition
LONDON & NEW YORK--(BUSINESS WIRE)--Genius Sports Limited (NYSE:GENI) (“Genius Sports,” “Genius” or the “Group”), the operating system of modern sport, today announced financial results for its fiscal first quarter ended March 31, 2026. “Our first quarter results underscore the durability and visibility of our business model, with strong revenue growth across both Betting and Media driven by long-term contracts, expanding customer relationships, and delivery of new products across the global sp...
Shift4 Announces First Quarter 2026 Results
CENTER VALLEY, Pa.--(BUSINESS WIRE)---- $FOUR--Shift4 (NYSE: FOUR) has posted its first quarter 2026 financial results as part of its Q1 2026 Shareholder Letter, which can be viewed here or by navigating to the Financials section of its Investor Relations website at https://investors.shift4.com. Earnings Conference Call Management will host a conference call today, May 7th, 2026, at 8:30 a.m. ET to discuss the results. Conference Call Details Toll-free dial-in: +1-800-274-8461 Toll dial-in: +1-203-51...
MRI‑Simmons and Experian Expand Collaboration to Bring Research‑Based Audiences to Experian's Data Marketplace
NEW YORK--(BUSINESS WIRE)--Today, MRI‑Simmons announced an expanded collaboration with Experian, a leading global data and technology company, to make audience segments derived from MRI‑Simmons' nationally representative consumer research available through Experian's data marketplace. The collaboration enables advertisers, agencies, and media owners to access audiences informed by MRI‑Simmons' consumer research, then activate those audiences at scale through Experian's platform and distribution...
Better Home & Finance Holding Company Announces First Quarter 2026 Results
NEW YORK--(BUSINESS WIRE)---- $BETR #BETR--Better Home & Finance Holding Company (NASDAQ: BETR; BETRW) (“Better,” the “Company,” “our” or “we”), the AI-native mortgage and home equity finance company, today reported financial results for the first quarter ended March 31, 2026. “Q1 2026 was a strong quarter for Better. We grew loan volume 89% year over year and exceeded the high end of our previously-issued guidance with revenue up 52% year over year. Tinman AI platform volume made up 50% of our loan volume...
Charles River Laboratories Announces First-Quarter 2026 Results
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces First-Quarter 2026 Financial Results.
Evergy Announces First Quarter 2026 Results, Announces New Large Customer, Declares Quarterly Dividend and Reaffirms 2026 Guidance
KANSAS CITY, Mo.--(BUSINESS WIRE)--Evergy, Inc. (NASDAQ: EVRG) today announced first quarter 2026 GAAP earnings of $151.5 million, or $0.64 per share, compared to GAAP earnings of $125.0 million, or $0.54 per share, for the first quarter 2025. Evergy's first quarter 2026 adjusted earnings (non-GAAP) and adjusted earnings per share (non-GAAP) were $161.8 million and $0.69 per share, respectively, compared to $127.8 million and $0.55, respectively, in first quarter 2025. Adjusted earnings (non-GA...
BKV Corporation Reports First Quarter 2026 Financial and Operational Results
DENVER--(BUSINESS WIRE)--BKV Corporation (“BKV” or the “Company”) (NYSE: BKV), today reported financial and operational results for the first quarter of 2026. First Quarter 2026 Highlights Net income attributable to BKV of $44.1 million or $0.42 per diluted share Adjusted Net Income attributable to BKV of $22.4 million or $0.22 per diluted share Adjusted EBITDAX attributable to BKV of $112.0 million Net cash provided by operating activities of $72.0 million Net cash provided by operating activi...
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results.
Shake Shack Announces First Quarter 2026 Financial Results
NEW YORK--(BUSINESS WIRE)--Shake Shack Inc. (“Shake Shack” or the “Company”) (NYSE: SHAK) has posted its results for the first quarter of 2026 in a Shareholder Letter in the Quarterly Results section of the Company's Investor Relations website, which can be found here: Q1 2026 Shake Shack Shareholder Letter. Shake Shack will host a conference call at 8:00 a.m. ET. Hosting the call will be Robert Lynch, Chief Executive Officer. The conference call can be accessed live over the phone by dialing (...
Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today reported financial results for the first quarter ended March 31, 2026, and provided an update on recent company developments. “With the FDA's acc...
Xeris Biopharma Reports First Quarter 2026 Financial Results
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS.
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene) in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS) with or without concomitant papillary d...
Lee Enterprises Reports Strong Second Quarter Results
95% YOY Adjusted EBITDA(1) growth in Q2Digital revenue(2) represents 56% of total revenue in Q2Improved capital structure; $53M in cash & interest rate(3) reduced to 5%Reaffirms guidance of YOY Adjusted EBITDA growth in FY26 DAVENPORT, Iowa, May 07, 2026 (GLOBE NEWSWIRE) -- Lee Enterprises, Incorporated (NASDAQ: LEE), a digital-first subscription platform providing high quality, trusted, local news, information and a major platform for advertising in 114 markets, today reported preliminary second quarter fiscal 2026 financial results(4) for the period ended March 29, 2026. "Our second quarter results reflect continued momentum in the business and disciplined execution across our operations," said Nathan Bekke, Lee's President and Chief Executive Officer...
Jumia Reports First Quarter 2026 Results
Jumia Reports 32%[1] GMV Growth and 39% Revenue Increase; Adjusted EBITDA Loss Narrowed 32%, Reflecting Continued Progress Toward Profitability; Jumia Reaffirms 2026 Guidance LAGOS, NIGERIA / ACCESS Newswire / May 7, 2026 / Jumia Technologies AG (NYSE:JMIA) ("Jumia" or the "Company") announced today its financial results for the first quarter ended March 31, 2026. Financial highlights for the first quarter 2026 Revenue of $50.6 million compared to $36.3 million in the first quarter of 2025, up 39% year-over-year, and up 28% in constant currency...
Eagle Plains Expands George Lake Deposit Mineralization, Reports 3.48% Zn+Pb over 45.1m in Step-out Drilling
CRANBROOK, BC / ACCESS Newswire / May 7, 2026 / Eagle Plains Resources Ltd. (TSXV:EPL)(OTCQB:EGPLF) ("EPL" or "Eagle Plains") is pleased to report that assay results have been received from its maiden drill program at its 100% owned George Lake Project.
Allegro MicroSystems Reports Fourth Quarter and Fiscal Year 2026 Results
Fourth Quarter Sales Increased by 26% Year-over-Year to $243 Million Fiscal Year 2026 Sales Increased by 23% Year-over-Year to $890 Million
Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
BEDFORD, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its first quarter ended March 31, 2026...
Gamma Resources Appoints Connor Messler as President
VANCOUVER, BC / ACCESS Newswire / May 7, 2026 / Gamma Resources Ltd. (TSXV:GAMA)(OTCQB:GAMXF)(FRA:MRD0) ("Gamma" or the "Company") is pleased to announce the appointment of Connor Messler as President of the Company, effective immediately.
EV Nickel Reports Significant High-Grade Intersection of 34.60m Grading 1.06% Nickel at Langmuir #2
EV26-L08 intersected 34.60m grading 1.06% Ni, incl. 13.70m grading 1.76% Ni, 5.60m grading 3.00% Ni Intercept confirms down plunge extension of high grade nickel sulphides at Langmuir #2 All 3 holes on Langmuir South Zone intersect significant nickel mineralization Holes L06 and L07 intersect additional high-nickel tenors sulphides associated with Langmuir South TORONTO, ON / ACCESS Newswire / May 7, 2026 / EV NICKEL INC...
Microbix Schedules Release of Results for Q2 Fiscal 2026
Results Release and Webinar Discussion on Morning of May 14, 2026 MISSISSAUGA, ON / ACCESS Newswire / May 7, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2026 ended March 31, 2026 ("Q2 2026") prior to the start of trading on May 14, 2026. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q2 2026 results with its CEO, CFO, and COO...
Apyx Medical Corporation Reports First Quarter 2026 Financial Results
CLEARWATER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion and the AYON Body Contouring System™ (AYON), today reported financial results for its first quarter ended March 31, 2026...
Antimony Resources Corp. (ATMY) (ATMYF) (K8J0) Is Pleased to Announce the Next Phase of Exploration at the Bald Hill Antimony Deposit in New Brunswick, Canada
Focus of the Drilling will be on Expansion Drilling not Definition Drilling. Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - Antimony Resources Corp. (CSE: ATMY) (OTCQB: ATMYF) (FSE: K8J0) (the "Company" or "Antimony Resources" or "ATMY") is pleased to announce that it will be commencing the next phase of exploration at the Bald Hill Antimony Project in the second week of May...
MSC Income Fund Announces Transition from Quarterly to Monthly Regular Dividends Beginning in July 2026
Declares Regular Monthly Dividends of $0.11 Per Share for each of July, August and September 2026 and Supplemental Dividend of $0.03 Per Share Payable September 2026 HOUSTON, May 7, 2026 /PRNewswire/ -- MSC Income Fund, Inc. (NYSE: MSIF) (the "Fund") is pleased to announce a change to its regular dividend payment frequency from quarterly to monthly beginning in July 2026. In addition, the Fund is pleased to announce that its Board of Directors declared regular monthly cash dividends of $0.11 per share payable in July, August and September 2026...
Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2026
Cash Increased Sequentially by $468,000 to $18 Million Plans to Achieve Cash Flow Positive in Second Half of Calendar Year 2026 Business Stabilized Following Strategic Repositioning Phased Roadmap Targets Billions in Addressable Market, Including ~$73B Global Vape, ~$50–70B U.S. Flavored Vape, and $24B+ Global G-Mesh Glass Technology LOS ANGELES, May 7, 2026 /PRNewswire/ -- Ispire Technology Inc. (Nasdaq: ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2026, for the three months ended March 31, 2026. Michael Wang, Co-Chief Executive Officer of Ispire, commented, "This quarter reflects the successful stabilization of our business and with cash growing sequentially by $468,000 to $18 million, we are now executing against a phased roadmap, with near-term revenue drivers already in production and transformative technology opportunities on the horizon: Our Malaysia manufacturing is live today, giving us a 25% tariff advantage over China in a ~$73B global vape market...
Obsidian Energy Announces First Quarter 2026 Results
Average production of 28,733 boe/d in the first quarter, generated $61.0 million of funds flow from operations Active development program in Peace River and Willesden Green while advancing strategic heavy oil waterflood initiatives Renewed normal course issuer bid and repurchased and cancelled ~1.5 million shares Calgary, Alberta--(Newsfile Corp. - May 7, 2026) - OBSIDIAN ENERGY LTD. (TSX: OBE) (NYSE American: OBE) ("Obsidian Energy", the "Company", "we", "us" or "our") is pleased to report our operating and financial results for the first quarter of 2026...
Onyx to Host Webinar on May 14, 2026 at 10:00am PT/1:00pm ET to Provide Update on Munro-Croesus Drill Program
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - Onyx Gold Corp. (TSXV: ONYX) (OTCQX: ONXGF) ("Onyx" or the "Company") will be hosting an exploration and technical webinar on May 14, 2026 at 10:00am PT / 1:00 pm ET to provide an in-depth update on the Company's ongoing and expanded 110,000 m drill program at its 100%-owned Munro-Croesus Project, located 75 km east of Timmins, Ontario. Onyx President & CEO, Brock Colterjohn, and VP Exploration, Conor McKinley, will review recent drilling results, key geological developments, and emerging exploration trends identified through the program to date...
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
— Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025— — ARIKAYCE (amikacin liposome inhalation suspension) Revenues of $98.1 Million for the First Quarter of 2026, Reflecting 6% Growth Over the First Quarter of 2025— —Company Reiterates 2026 BRINSUPRI Revenue Guidance of at Least $1 Billion and 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million— — Phase 3b ENCORE Study of ARIKAYCE in Patients with MAC Lung Disease Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints— —Phase 3 PALM-PAH Study of TPIP in Patients with PAH Initiated in April 2026— BRIDGEWATER, N.J., May 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update...
SuperQ Quantum Secures Major Commercial Agreement with AI Financial (AIFC) to Implement Post-Quantum Security and Compute Tokenization
Calgary, Alberta--(Newsfile Corp. - May 7, 2026) - SuperQ Quantum Computing Inc. (CSE: QBTQ) (OTCQB: QBTQF) (FSE: 25X) ("SuperQ Quantum", "SuperQ", or the "Company"), a global leader in hybrid quantum computing and post-quantum cybersecurity, is pleased to announce securing a commercial agreement of significant size with AI Financial Corporation ("AiFi", formerly ALT5 Sigma Corporation) (NASDAQ: AIFC) a world leader in B2B and AI agent-to-agent digital finance. Securing the $8 Billion Institutional Transactions and $WLFI Treasury AiFi processed USD $3.5B in transactions in 2025, growing at a four-year CAGR of 66.5%...
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advances AP-SA02 on a faster path to potential approval and patient access LOS ANGELES, May 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation to AP-SA02, the Company's intravenously administered Staphylococcus aureus ("S. aureus") multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S...
Evolent Announces First Quarter 2026 Results
WASHINGTON, May 7, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2026. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "I am happy with the strong start to the year...
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected to Initiate in Second Half of 2026 Data from Phase 1/2 BEACON Clinical Trial of Risto-cel in Sickle Cell Disease Published in April 1 Issue of the New England Journal of Medicine; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Investigational New Drug (IND) Application for BEAM-304 in PKU and Data from BEAM-301 in GSDIa Anticipated in 2026 Ended First Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into mid-2029 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2026 financial results and provided updates across the company's hematology and genetic disease franchises...
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed - dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Completed enrollment in REMBRANDT; Topline data from RUBENS Phase 3 expected by year-end 2026 – – Presented new analyses of Phase 3 BROOKLYN and BROADWAY studies at the American College of Cardiology Annual Scientific Session (ACC) and simultaneously published in the American Journal of Preventative Cardiology– – $707.3 million in cash, cash equivalents and marketable securities at March 31, 2026 – – Management to host PREVAIL update call today at 8:00 AM ET – NAARDEN, the Netherlands and MIAMI, May 07, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced financial results for the quarter ended March 31, 2026 and provided a corporate update...